DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for ossifying fibroma — screening already-approved drugs against its 9-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOssifying fibroma maps to a 9-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for ossifying fibroma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) — PIK3CA is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2sdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4JPS · 2.2 Å · ligand (2S)-N~1~-{4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl}pyrrolidine-1,2-dicarboxamide (1LT). Experimental structure, not a prediction.
What the evidence adds up to
Ossifying fibroma is described as a benign fibro-osseous lesion of the facial bones, but it can behave aggressively locally and has a higher recurrence nature. One case report notes that its rapid progression and osteolytic appearance can create a diagnostic challenge, giving the impression of a malignant lesion. A separate report on peripheral ossifying fibroma describes that variant as a non-neoplastic reactive lesion of the gingiva, arising from hyperplasia in response to local irritants such as oral microbes, dental plaque, occlusal trauma, and food debris.
A retrospective descriptive study at Dr. Hasan Sadikin General Hospital from 2019 to 2021 identified 17 patients with histopathologically confirmed ossifying fibroma. Of these, 13 were female (76.47%). The average age was 27.87 years with a standard deviation of 19.49. Most lesions were located in the mandible (11 patients, 64.71%). Among mandibular defects, type I was most common (5 patients, 45.45%); among maxillary defects, type II was most common (2 patients, 40%). The most frequent treatment was dredging, performed in 4 patients (23.53%). The study notes that surgical treatment for ossifying fibroma carries its own complications, resulting in defects in the affected area.
No drug treatment is mentioned in any of these abstracts. The literature consists entirely of case reports and a small retrospective case series. What is missing is any prospective trial, any pharmacological intervention, any data on recurrence rates after specific treatments, and any stratification of patients by lesion subtype or genetic markers.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Dental Specialities · 2019 · 48 citations · open access
Peripheral ossifying fibroma- A case report
AbstractGingival enlargement, also called gingival overgrowth, is the thickening of gum tissues that surrounds the teeth. The etiology of gingival growths may vary from reactive gingival enlargement in response to drugs to neoplastic lesions. Peripheral ossifying fibroma (POF) is a reactive lesion found on the gingiva and non-neoplastic in nature. This lesion is non neoplastic but occurs as a result of hyperplasia in response to oral microbes, dental plaque, occlusal trauma, local irritation, masticatory forces, dental calculus, and food debris. The purpose of this case report is to briefly overview clinical and histopathological features of POF in a 38 year old female patient and discuss the lesion in detail. Keywords: Gingival overgrowth, Neoplasm, Peripheral ossifying fibroma, Hyperplasia
International Journal of Medical and Biomedical Studies · 2024 · 0 citations · open access
Characteristics and Treatment of Ossifying Fibroma at Dr. Hasan Sadikin General Hospital during 2019 – 2021
AbstractIntroduction: Ossifying fibroma is a benign neoplasm commonly found in the bones of the face and has the potential for excessive growth, causing bone destruction and recurrence. Treatment for ossifying fibroma itself has their own complications which result as defect in the area that were affected on surgery. Even so, characteristics and treatment of ossifying fibroma itself differs in distinct population. Therefore, it was important to study the characteristic and treatment of ossifying fibroma at Dr. Hasan Sadikin General Hospital during 2019 – 2021. Methods: The sample in this study patients that are diagnosed by histopathologic finding to be with ossifying fibroma during January of 2019 until December of 2021 at Dr. Hasan Sadikin General Hospital. There were 17 patients that met the inclusion criteria. This study was conducted using total sampling method and is a retrospective descriptive study using medical records of patients that met the inclusion criteria. Results: Based on the gender criteria, most of the ossifying fibroma patients were female, with the total of 13 female respondents. The average age on this study is 27,87 with 19,49 deviation standards. Based on the classifications of defects, most of the mandibular defect respondents have type I mandibular defect, with total of five respondents. Meanwhile, most maxillary defect respondents have type II maxillary defect, which there were two respondents. Based on the location of the lesion itself, most of the lesion were found in mandibular, with 11 respondents. Particularly, based on the treatment received by the respondents, most respondents went under dredging treatment, with about four people underwent dredging. Conclusion: Most of the ossifying fibroma patients were female (76,47%). The average age on this study is 27,87 with 19,49 deviation standards. Most of the mandibular and maxillary defect are type I mandibular defect (45,45%) and type II maxillary defect (40%). Most of the lesion were found in mandibular (64.71%). and most respondents went under dredging treatment (23,53%). Keywords: ossifying fibroma, patients characteristics, treatment.
International Archives of Dental Sciences · 2009 · 0 citations · open access
Ossifying Fibroma in the Upper Jaw: Case Report
AbstractOssifying fibroma is demarcated lesion of fibrous tissue with varying amounts of mineralized material resembling bone and/or cementum.This report presented a 31-year-old female patient with a large ossifying fibroma of the maxilla.In addition, the report discussed the clinician's role in correct diagnosis and the importance of biopsy for the correct management was emphasized.
Online Journal of Otolaryngology and Rhinology · 2018 · 0 citations · open access
Ossifying Fibroma of Nasal Cavity: A Rare Case Report
AbstractOssifying fibroma is a rare benign fibro-osseous lesion more commonly seen in the head and neck regions. Despite a benign lesion, it behaves aggressively locally and possess higher recurrence nature. One may have a diagnostic challenge owing to its rapid progression and osteolytic nature and having the impression of malignant lesion.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
